Animal Models of the Non-motor Features of Parkinson's Disease

Overview

Journal Neurobiol Dis

Specialty Neurology

Date 2012 Jan 13

PMID 22236386

Citations 64

Authors

Kimberly McDowell

Marie-Francoise Chesselet

Affiliations

Soon will be listed here.

Abstract

The non-motor symptoms (NMS) of Parkinson's disease (PD) occur in roughly 90% of patients, have a profound negative impact on their quality of life, and often go undiagnosed. NMS typically involve many functional systems, and include sleep disturbances, neuropsychiatric and cognitive deficits, and autonomic and sensory dysfunction. The development and use of animal models have provided valuable insight into the classical motor symptoms of PD over the past few decades. Toxin-induced models provide a suitable approach to study aspects of the disease that derive from the loss of nigrostriatal dopaminergic neurons, a cardinal feature of PD. This also includes some NMS, primarily cognitive dysfunction. However, several NMS poorly respond to dopaminergic treatments, suggesting that they may be due to other pathologies. Recently developed genetic models of PD are providing new ways to model these NMS and identify their mechanisms. This review summarizes the current available literature on the ability of both toxin-induced and genetically-based animal models to reproduce the NMS of PD.

Citing Articles

CCL21-CCR7 blockade prevents neuroinflammation and degeneration in Parkinson's disease models.

Leser F, Junyor F, Pagnoncelli I, Delgado A, Medeiros I, Nobrega A J Neuroinflammation. 2025; 22(1):31.

PMID: 39894839 PMC: 11789347. DOI: 10.1186/s12974-024-03318-x.

Cold-pressed perilla seed oil: Investigating its protective influence on the gut-brain axis in mice with rotenone-induced Parkinson's disease.

Techaniyom P, Korsirikoon C, Rungruang T, Pakaprot N, Prombutara P, Mukda S Food Sci Nutr. 2024; 12(9):6259-6283.

PMID: 39554352 PMC: 11561828. DOI: 10.1002/fsn3.4265.

Construct, Face, and Predictive Validity of Parkinson's Disease Rodent Models.

Guimaraes R, Resende M, Tavares M, Belardinelli de Azevedo C, Ruiz M, Mortari M Int J Mol Sci. 2024; 25(16).

PMID: 39201659 PMC: 11354451. DOI: 10.3390/ijms25168971.

Role of Astrogliosis in the Pathogenesis of Parkinson's Disease: Insights into Astrocytic Nrf2 Pathway as a Potential Therapeutic Target.

Bhushan B, Singh N CNS Neurol Disord Drug Targets. 2023; 23(8):1015-1029.

PMID: 37817521 DOI: 10.2174/0118715273270473231002104610.

Anxiety in synucleinopathies: neuronal circuitry, underlying pathomechanisms and current therapeutic strategies.

Thi Lai T, Gericke B, Feja M, Conoscenti M, Zelikowsky M, Richter F NPJ Parkinsons Dis. 2023; 9(1):97.

PMID: 37349373 PMC: 10287685. DOI: 10.1038/s41531-023-00547-4.

References

Glatt C, Wahner A, White D, Ruiz-Linares A, Ritz B . Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women. Hum Mol Genet. 2005; 15(2):299-305. PMC: 3643966. DOI: 10.1093/hmg/ddi445. View

Polymeropoulos M, Lavedan C, Leroy E, Ide S, Dehejia A, Dutra A . Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997; 276(5321):2045-7. DOI: 10.1126/science.276.5321.2045. View

Santiago R, Barbieiro J, Lima M, Dombrowski P, Andreatini R, Vital M . Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson's disease are predominantly associated with serotonin and dopamine. Prog Neuropsychopharmacol Biol Psychiatry. 2010; 34(6):1104-14. DOI: 10.1016/j.pnpbp.2010.06.004. View

Litteljohn D, Mangano E, Hayley S . Cyclooxygenase-2 deficiency modifies the neurochemical effects, motor impairment and co-morbid anxiety provoked by paraquat administration in mice. Eur J Neurosci. 2008; 28(4):707-16. DOI: 10.1111/j.1460-9568.2008.06371.x. View

Halliday G, Lees A, Stern M . Milestones in Parkinson's disease--clinical and pathologic features. Mov Disord. 2011; 26(6):1015-21. DOI: 10.1002/mds.23669. View

Bassetti C . Nonmotor disturbances in Parkinson's disease. Neurodegener Dis. 2011; 8(3):95-108. DOI: 10.1159/000316613. View

Bronstein J, Tagliati M, Alterman R, Lozano A, Volkmann J, Stefani A . Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Arch Neurol. 2010; 68(2):165. PMC: 4523130. DOI: 10.1001/archneurol.2010.260. View

Lim Y, Kehm V, Lee E, Soper J, Li C, Trojanowski J . α-Syn suppression reverses synaptic and memory defects in a mouse model of dementia with Lewy bodies. J Neurosci. 2011; 31(27):10076-87. PMC: 3144489. DOI: 10.1523/JNEUROSCI.0618-11.2011. View

Gerlach M, Maetzler W, Broich K, Hampel H, Rems L, Reum T . Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics. J Neural Transm (Vienna). 2011; 119(1):39-52. PMC: 3250615. DOI: 10.1007/s00702-011-0682-x. View

10.

Halliday G, Blumbergs P, Cotton R, Blessing W, Geffen L . Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease. Brain Res. 1990; 510(1):104-7. DOI: 10.1016/0006-8993(90)90733-r. View

11.

Goldstein D, Li S, Holmes C, Bankiewicz K . Sympathetic innervation in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of Parkinson's disease. J Pharmacol Exp Ther. 2003; 306(3):855-60. DOI: 10.1124/jpet.103.051714. View

12.

Prediger R, Aguiar Jr A, Rojas-Mayorquin A, Figueiredo C, Matheus F, Ginestet L . Single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice models early preclinical phase of Parkinson's disease. Neurotox Res. 2009; 17(2):114-29. DOI: 10.1007/s12640-009-9087-0. View

13.

Bonifati V, Rizzu P, van Baren M, Schaap O, Breedveld G, Krieger E . Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science. 2002; 299(5604):256-9. DOI: 10.1126/science.1077209. View

14.

Taylor T, Caudle W, Shepherd K, Noorian A, Jackson C, Iuvone P . Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity. J Neurosci. 2009; 29(25):8103-13. PMC: 2813143. DOI: 10.1523/JNEUROSCI.1495-09.2009. View

15.

Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman E, Mizuno Y . Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci U S A. 1996; 93(7):2696-701. PMC: 39693. DOI: 10.1073/pnas.93.7.2696. View

16.

Abbott R, Ross G, Petrovitch H, Tanner C, Davis D, Masaki K . Bowel movement frequency in late-life and incidental Lewy bodies. Mov Disord. 2007; 22(11):1581-6. DOI: 10.1002/mds.21560. View

17.

Fleming S, Salcedo J, Hutson C, Rockenstein E, Masliah E, Levine M . Behavioral effects of dopaminergic agonists in transgenic mice overexpressing human wildtype alpha-synuclein. Neuroscience. 2006; 142(4):1245-53. PMC: 3108485. DOI: 10.1016/j.neuroscience.2006.07.005. View

18.

Kehagia A, Barker R, Robbins T . Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol. 2010; 9(12):1200-1213. DOI: 10.1016/S1474-4422(10)70212-X. View

19.

Kim R, Smith P, Aleyasin H, Hayley S, Mount M, Pownall S . Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. Proc Natl Acad Sci U S A. 2005; 102(14):5215-20. PMC: 555037. DOI: 10.1073/pnas.0501282102. View

20.

Kingsbury A, Bandopadhyay R, Silveira-Moriyama L, Ayling H, Kallis C, Sterlacci W . Brain stem pathology in Parkinson's disease: an evaluation of the Braak staging model. Mov Disord. 2010; 25(15):2508-15. DOI: 10.1002/mds.23305. View